Alcohol and Metabolism: A Deadly Duo for Your Liver!

Alcohol consumption can have serious health consequences, particularly when combined with metabolic disorders. Alcohol plays a significant role in the development of liver diseases such as hepatic steatosis and steatohepatitis, which can progress to cirrhosis or liver cancer if left untreated. When combined with conditions like obesity, type 2 diabetes, and hypertension, the risk of severe liver disease increases significantly.

This study explores how alcohol, in conjunction with these metabolic dysfunctions, contributes to the development of specific alcohol-related liver diseases, termed MetALD (Metabolic Dysfunction-Associated Alcohol-Related Liver Disease).

The Combined Risks: Alcohol and Metabolic Dysfunctions

To identify the combined risks and differentiate liver diseases caused solely by alcohol (ALD) from those influenced by both alcohol and metabolic disorders (MetALD), the study evaluated patients’ alcohol consumption habits using biomarkers such as PEth and validated questionnaires. Input from relatives or healthcare professionals was also included. Metabolic factors like hypertension, diabetes, and hypertriglyceridemia were assessed, along with their interaction with alcohol.

The findings reveal that alcohol consumption is closely linked to cardiometabolic conditions such as hypertension, hypertriglyceridemia, and hyperglycemia. Alcohol exacerbates these risks, worsening metabolic dysfunction and liver health. Additionally, the study highlights that diagnosing MetALD requires precise identification of alcohol consumption patterns and metabolic risk factors. However, this diagnosis can be challenging due to variability in drinking behaviors.

Toward More Accurate Diagnosis and Better Management

The study emphasizes the importance of comprehensive alcohol consumption assessment using biomarkers like PEth and validated questionnaires to enhance diagnostic accuracy, particularly in patients with multiple risk factors. Continuous monitoring and strategies to reduce alcohol consumption could slow the progression of liver diseases. By clearly distinguishing MetALD from ALD, treatments and patient management can be optimized to address combined risk factors effectively.